Maa: Malta
Kieli: englanti
Lähde: Medicines Authority
PARACETAMOL, TRAMADOL HYDROCHLORIDE
Zentiva k.s. U kabelovny 130, Dolní Mecholupy, 102 37 Praha 10, Czech Republic
N02AJ13
PARACETAMOL 650 mg TRAMADOL HYDROCHLORIDE 75 mg
FILM-COATED TABLET
PARACETAMOL 650 mg TRAMADOL HYDROCHLORIDE 75 mg
POM
ANALGESICS
Withdrawn
2014-05-12
Page 1 of 8 PACKAGE LEAFLET: INFORMATION FOR THE USER PALGOTAL 75 MG / 650 MG FILM-COATED TABLETS tramadol hydrochloride / paracetamol READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Palgotal is and what it is used for 2. What you need to know before you take Palgotal 3. How to take Palgotal 4. Possible side effects 5. How to store Palgotal 6. Contents of the pack and other information 1. WHAT PALGOTAL IS AND WHAT IT IS USED FOR Palgotal contains two pain relieving active substances: tramadol and paracetamol. Palgotal is used to treat moderate to severe pain when your doctor recommends that a combination of tramadol and paracetamol is needed. Palgotal is intended for adults and adolescents over 12 years of age. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE PALGOTAL DO NOT TAKE PALGOTAL if you are ALLERGIC to tramadol, paracetamol or any of the other ingredients of this medicine (listed in section 6). in cases of ACUTE POISONING with alcohol, sleeping pills, pain relievers or psychotropic drugs (that affect mood, emotions and state of mind). if you are also taking medicines called MONOAMINE OXIDASE INHIBITORS (MAOIs) or have taken MAOIs IN THE LAST 14 DAYS before treatment with Palgotal. MAOIs are used in the treatment of depression or Parkinson’s disease. if you have a SEVERE LIVER DISORDER . if you have EPILEPSY that is not adequately controlled by your current medicine. Page 2 of 8 WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before taking Palgotal> i Lue koko asiakirja
Page 1 of 13 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Palgotal 75 mg / 650 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 75 mg tramadol hydrochloride and 650 mg paracetamol. Excipient with known effect: Each tablet contains 1.9 mg sodium. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. Slightly yellowish brown, oblong, biconvex film-coated tablets, half-scored on both sides with dimensions 18×9 mm, radius 8 mm. The tablet can be divided into equal doses. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Palgotal is indicated for the symptomatic treatment of moderate to severe pain in adults and adolescents over the age of 12 years. The use of Palgotal should be restricted to patients whose moderate to severe pain is considered to require a combination of tramadol and paracetamol (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults and adolescents (12 years and older) _ The use of Palgotal should be restricted to patients whose moderate to severe pain is considered to require a combination of tramadol and paracetamol. The dose should be adjusted to the intensity of the pain and the sensitivity of the individual patient. The lowest effective dose for analgesia should generally be selected. An initial dose of one tablet of Palgotal is recommended. Additional doses can be taken as needed, not exceeding 4 tablets (equivalent to 300 mg tramadol and 2,600 mg paracetamol) per day. The dosing interval should not be less than six hours. Page 2 of 13 Palgotal should under no circumstances be administered for longer than is strictly necessary (see section 4.4). If repeated use or long term treatment with Palgotal is required as a result of the nature and severity of the illness, then careful, regular monitoring should take place (with breaks in the treatment, where possible), to assess whether continuation of the treatment is necessary. _Paediatric population _ The effective and safe u Lue koko asiakirja